Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
JUPITER NEUROSCIENCES, INC. Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.	United States of America	JUNS
JW LIFESCIENCE CORPORATION A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.	South Korea	234080
JW SHINYAK CORPORATION Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.	South Korea	067290
Jyong Biotech Ltd. Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.	United States of America	MENS
Kadimastem Ltd. Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.	Israel	KDST
kainos loboratories,inc Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.	Japan	4556
Kairos Pharma, LTD. Develops novel oncology therapies to reverse drug resistance and immune suppression.	United States of America	KAPA
KAKEN PHARMACEUTIAL CO., LTD. R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.	Japan	4521
KALA BIO, Inc. Developing stem cell-based biologics for rare and serious eye diseases.	United States of America	KALA
KalVista Pharmaceuticals, Inc. Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).	United States of America	KALV